A Scottish biotech firm behind a platform that could revolutionise the early diagnosis and monitoring of difficult-to-detect cancers has raised £1.6 million in a fresh funding round and launched its first product in the US.
Its latest financing round was led by existing investor Archangels, with support from Old College Capital, BBI, Scottish Enterprise and new investor EverQuest Capital Partners.
Read more HERE.
